Urgent efforts are taking place across the country to identify potential treatments for COVID-19. One of the potential treatments reported on by the media has been hydroxychloroquine (Plaquenil). Following this, many people living with rheumatic diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), vasculitis, Sjögren’s Disease, and other autoimmune rheumatic conditions, have reported difficulties in accessing their medications. To raise awareness of the implications of these shortages, CAPA took the lead in drafting a joint letter with key partners which was sent to the Minister of Health on April 5, 2020.